Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02734771 · ClinicalTrials.gov registry record · Phase 2

A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase 2 study of Diffuse Large B Cell Lymphoma, sponsored by Patrick Reagan.

Active
Registry status
Phase 2
Development phase
24
Enrollment target
2
Study locations

NCT02734771: Active Phase 2 study of Diffuse Large B Cell Lymphoma, sponsored by Patrick Reagan.

NCT02734771 is a Phase 2 study of Diffuse Large B Cell Lymphoma that is active but no longer recruiting, run by Patrick Reagan. The registered enrollment target is 24 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02734771, a Phase 2 study of Diffuse Large B Cell Lymphoma, is active but no longer recruiting, sponsored by Patrick Reagan.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
24 participants
Enrollment target
2
Study locations

Study Summary

This is a study incorporating brentuximab vedotin and dose attenuated rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) into initial therapy for elderly patients with DLBCL. Vincristine will be omitted from the standard R-CHOP regimen given the overlapping toxicities with brentuximab vedotin.

Primary Outcome

Number of subjects who complete all 6 cycles of the therapy divided by the total number of subjects.

Conditions Studied

Diffuse Large B Cell Lymphoma

Interventions

  • DRUG Cyclophosphamide
  • DRUG Doxorubicin
  • DRUG Rituximab
  • DRUG Prednisone
  • DRUG Brentuximab vedotin

Study Locations (2)

New York

  • James P. Wilmot Cancer Institute, University of Rochester Medical Center - Rochester

Virginia

  • University of Virginia Cancer Center - Charlottesville

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2016-06
Est. Completion 2025-12
Phase Phase 2
Patrick Reagan

1 total trials

What the registry record for NCT02734771 still lists

NCT02734771 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT02734771 reports a single indexed study location in New York, Virginia.

Frequently Asked Questions

What is clinical trial NCT02734771 about?

NCT02734771 is a clinical study titled "A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)". This is a study incorporating brentuximab vedotin and dose attenuated rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) into initial therapy for elderly patients with DLBCL. Vincristine will be omitted from the standard R-CHOP regimen given the overlapping toxicities with brentuximab ...

What is the current status of trial NCT02734771?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2016-06. Estimated completion is 2025-12.

What conditions does trial NCT02734771 study?

This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.

What interventions are being tested in trial NCT02734771?

The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Rituximab (DRUG), Prednisone (DRUG), Brentuximab vedotin (DRUG).

Who is sponsoring clinical trial NCT02734771?

This trial is sponsored by Patrick Reagan, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02734771 being conducted?

This trial has 2 study locations across New York, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diffuse Large B Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02734771's enrollment target sits among peer trials

24 89th of 114 higher than 23 of 114 other Diffuse Large B Cell Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diffuse Large B Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02734771, the US trial registry maintained by the National Library of Medicine. NCT02734771 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.